Calamos Advisors LLC Sells 12,760 Shares of Novo Nordisk A/S $NVO

Calamos Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 11.5% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 98,472 shares of the company’s stock after selling 12,760 shares during the quarter. Calamos Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,619,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. CIBC Bancorp USA Inc. purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at approximately $19,519,000. Romano Brothers AND Company raised its holdings in shares of Novo Nordisk A/S by 704.0% during the 4th quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock worth $1,742,000 after acquiring an additional 29,978 shares in the last quarter. Capital Investment Counsel LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $3,727,000. Marathon Capital Management grew its holdings in shares of Novo Nordisk A/S by 43.9% in the fourth quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock valued at $4,208,000 after purchasing an additional 25,230 shares in the last quarter. Finally, CWA Asset Management Group LLC increased its position in Novo Nordisk A/S by 131.9% in the fourth quarter. CWA Asset Management Group LLC now owns 76,993 shares of the company’s stock worth $3,917,000 after purchasing an additional 43,793 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of recent research reports. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday. Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target for the company. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Five research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Up 3.0%

Shares of NYSE NVO opened at $50.56 on Thursday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $71.79. The firm has a 50-day simple moving average of $45.89 and a two-hundred day simple moving average of $45.80. The company has a market cap of $225.77 billion, a P/E ratio of 11.87, a PEG ratio of 4.48 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion for the quarter. Research analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk won EU approval for its once-daily Wegovy pill, making it the first oral GLP-1 weight-loss treatment cleared across the European Union and expanding its obesity market reach. Novo Nordisk wins EU approval for Wegovy weight-loss pill
• Positive Sentiment: Novo Nordisk updated investors on a large Phase 3 heart failure-obesity study, suggesting continued pipeline progress in cardiometabolic disease, a major long-term growth area. Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial
• Positive Sentiment: Fresh hemophilia trial results for Mim8/concizumab showed sustained efficacy and safety, expanding evidence for Novo’s rare blood disorder portfolio. Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children
• Positive Sentiment: Novo Nordisk said most patients are choosing its obesity pill over Eli Lilly’s newer entrant, reinforcing confidence in its competitive position in the weight-loss drug market. It’s been three months since Lilly launched its obesity pill. Most people are taking Novo’s pill instead.
• Neutral Sentiment: Novo Nordisk also signed an agreement to evaluate a semaglutide implant, an early-stage move that adds optionality but is too preliminary to affect near-term results. Novo Nordisk signs pact to assess semaglutide implant
• Negative Sentiment: Sun Pharma won South Africa approval to launch a generic version of semaglutide, highlighting rising competitive pressure on Novo’s diabetes and obesity blockbusters. India’s Sun Pharma wins South Africa approval to launch generic Ozempic
• Negative Sentiment: Zacks Research downgraded Novo Nordisk to “strong sell,” which could weigh on sentiment despite the company’s positive operating news. Novo Nordisk A/S was downgraded by Zacks Research from “hold” to “strong sell”

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.